Alzheimers

Stock Market

Biogen Surges on Alzheimer’s Drug News: How to Play the Stock

[ad_1] I have no idea who will win the global race for a successful Alzheimer’s drug but for the moment,…

Read More »
Enterprenuers

Alzheimer’s drug trial shown to slow cognitive decline in long fight against dementia

[ad_1] Alzheimer’s is the most common form of dementia, a general term for loss of memory, language, and other thinking…

Read More »
Dallas

New Drug Shows Signs of Slowing Cognitive Decline in Alzheimer’s Patients, Study Finds

[ad_1] An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear…

Read More »
Startups

Seattle startup with fresh approach to Parkinson’s and Alzheimer’s disease raises $96M

[ad_1] Microscopy image of neurons in the mouse brain. (Cajal Neuroscience Image) Cajal Neuroscience, a Seattle startup taking a unique…

Read More »
Business

Alzheimer’s drug shows promise in early results of study

[ad_1] Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment…

Read More »
Stock Market

Biogen stock explodes higher after potential ‘mega blockbuster’ Alzheimer’s drug study

[ad_1] Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study…

Read More »
Business

Eisai, Biogen say Alzheimer’s drug succeeds in slowing cognitive decline

[ad_1] Breadcrumb Trail Links PMN Business Author of the article: Reuters Deena Beasley and Julie Steenhuysen Article content Eisai Co…

Read More »
Startups

Seattle startup aiming to detect, treat Alzheimer’s and Parkinson’s disease raises cash

[ad_1] AltPep CEO and founder Valerie Daggett. (AltPep Photo) The news: University of Washington spinout AltPep recently raised $44.4 million,…

Read More »
Health

Scientists are studying if Covid PCR process can help test for Alzheimer’s

[ad_1] Biochemist Dr Francesco Aprile’ team study the behaviour of proteins involved in the disease at Imperial College London’s molecular…

Read More »
Chicago

Medicare recipients paying $10 a month more in part because HHS overestimated cost of covering Alzheimer’s drug Aduhelm

[ad_1] Medicare recipients would have been paying less this year than they are for Part B premiums if not for…

Read More »
Back to top button
Close